Protara Therapeutics (TARA) Current Deferred Revenue (2013)

Protara Therapeutics' (TARA) quarterly Current Deferred Revenue came in at $2.9 million in Q4 2013.

Protara Therapeutics (TARA) Current Deferred Revenue (2013) Analysis & Trends

Protara Therapeutics (TARA) has 1 years of Current Deferred Revenue data on file, last reported at $2.9 million in Q4 2013.

On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $2.9 million in Q4 2013; TTM through Dec 2013 was $2.9 million, a N/A change from a year earlier, with the FY2013 full-year figure at $2.9 million, changed N/A from the prior year.
Current Deferred Revenue for Q4 2013 stood at $2.9 million.
Over the last five years, Current Deferred Revenue for TARA reached as high as $2.9 million in Q4 2013 and fell as low as $2.9 million in Q4 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Protara Therapeutics	233.61 Mn	233.61 Mn	-

Download Data

Date	Value
Dec 31, 2013	2.95 Mn